43 patients with metastatic colorectal cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.
A phase II trial of 5-fluorouracil, folinic acid, vinorelbine in pretreated patients with metastatic colorectal cancer / Iaffaioli, R. V.; Facchini, G.; Tortoriello, A.; Caponigro, F.; Gesue, G.; Finizio, A.; Di Martino, N.; De Sena, G.; Antonelli, B.; Scaramellino, G.; Fei, L.; Santangelo, M.; Bucci, L.. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - 2:4(1995), pp. 513-516.
A phase II trial of 5-fluorouracil, folinic acid, vinorelbine in pretreated patients with metastatic colorectal cancer
Facchini G.;De Sena G.;Santangelo M.;
1995
Abstract
43 patients with metastatic colorectal cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
